Register for our free email digests:
Phil Greenfield
Editor

After studying engineering, Editor-In-Chief Phil Greenfield started reporting on the medtech sector as a science journalist in 1993, when digital health, TAVR and personalized medicine were pipe dreams. He has since worked across all areas of health-care publishing, as an editor, publisher and principal analyst, and has been responsible for launching intelligence-based products to medtech and pharma clients. Phil has written extensively on topics around diagnostic imaging, IVDs, cardiovascular devices, orthopedics, oncology, wound care, clinical trials and EU reimbursement, and has authored numerous market forecasting reports on subjects ranging from prostate cancer diagnostics and devices to transcatheter embolization systems. Phil has also recently worked as an independent consultant with medtech/healthtech companies and universities assessing markets and product opportunities. A keen cyclist and walker, he lives in Yorkshire, England, where the steep hills help him counterbalance his other loves of food and Belgian beer.
Writes for:
Latest From Phil Greenfield
Cantel Medical Snapped Up By Steris For $3.6Bn
The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.
Top 10 R&D Stories Of 2020: The Year Of Diagnostics And Telehealth
One of the few silver linings in a tumultuous year dominated by a global pandemic was the huge boost given to the diagnostics and telehealth sectors. But while new technologies for rapid testing for COVID-19 and remote monitoring tools dominated the headlines, there were also key developments in robotic surgery, early-stage cancer testing and cardiac arrhythmia treatment. Here are Medtech Insight’s most popular R&D stories in 2020.
Carmat To Launch Total Artificial Heart In Early 2021
After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.
UK’s QuantuMDx Invests £11M To Bring Forward Launch Of Rapid, Point-Of-Care DNA Analyzer
The COVID-19 pandemic has accelerated development of another new molecular diagnostic technology.
Belgian Start-Up Launches 3-Gram Sleep Test Device For At-Home Apnea Diagnosis
AI-powered device is designed to diagnose sleep disorders using a small sensor that sits on the chin.
Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.